Armstrong, MD, MPH, chief of dermatology, UCLA, discusses clinical trial findings from the phase 2b study on zasocitinib.

Some patients with psoriasis who were treated with guselkumab and achieved complete skin clearance experienced a persistent impact on quality of life.

Basel, Switzerland Friday, September 20, 2024, 13:00 Hrs [IST] ...

The global psoriasis therapeutics market revenue was around US$ 25.0 billion in 2022 and is estimated to reach US$ 55.8 billion by 2031, growing at a compound annual growth rate (CAGR) of 9.3% during ...

Researchers propose the term “polyclonal parapsoriasis en plaque” to describe these lesions, which can be distinguished from ...

Tremfya is now approved for the treatment of plaque psoriasis, active psoriatic arthritis and ulcerative colitis.

The Roivant company is dedicated to developing and commercializing innovative therapeutics in immune-dermatology.

1 This study suggests that diagnostic uncertainty may also contribute to delays in treatment and a higher disease burden ...

Organon & Co (NYSE:OGN) has agreed to acquire Roivant Sciences Ltd’s (NASDAQ:ROIV) Dermavant Sciences Ltd, which is focused ...

Organon enters agreement to acquire Dermavant including innovative VTAMA (tapinarof) cream, 1%, a novel, non-steroidal topical dermatologic therapy.

VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an additional ...

Alumis, a recent IPO, has ESK-001, a promising phase 3 TYK2 inhibitor for Psoriasis and SLE, showing superior efficacy and safety over existing treatments. ESK-001's allosteric inhibition offers high ...